Schroder Investment Management Group
SPRY icon

Schroder Investment Management Group’s ARS Pharmaceuticals SPRY Stock Holding History

Schroder Investment Management Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-151,608
Closed -$534K – 1383
2022
Q1 		$534K Sell
151,608
-9,565
-6% -$41.6K ﹤0.01% 1212
2021
Q4 		$1.07M Buy
161,173
+5,037
+3% +$40.9K ﹤0.01% 1021
2021
Q3 		$1.56M Sell
156,136
-7,619
-5% -$188K ﹤0.01% 1025
2021
Q2 		$5.06M Buy
163,755
+59,258
+57% +$1.9M 0.01% 826
2021
Q1 		$4.56M Sell
104,497
-11,540
-10% -$546K 0.01% 838
2020
Q4 		$5.38M Buy
+116,037
New +$3.88M 0.01% 786

Other funds holding SPRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Schroder Investment Management Group's SPRY Position: Q2 2022 in Review

Schroder Investment Management Group sold out of ARS Pharmaceuticals (SPRY) in Q2 2022, closing a stake of 151,608 shares — an estimated $534K sold.

Schroder Investment Management Group first reported a position in SPRY in Q4 2020 and held it in 6 quarters. The position peaked at $5.38M in Q4 2020. 64 funds tracked by Wall St. Rank hold SPRY as of Q2 2022.

  • Schroder Investment Management Group reported no remaining ARS Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Schroder Investment Management Group sold 151,608 ARS Pharmaceuticals shares in Q2 2022, an estimated $534K.
  • Schroder Investment Management Group first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • Schroder Investment Management Group's ARS Pharmaceuticals position peaked at $5.38M in Q4 2020.
  • 64 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2022.

Based on Schroder Investment Management Group's 13F filing for Q2 2022, filed 11 Aug 2022.